Is CERO or JAGX more profitable?

CERo Therapeutics has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -169.04%. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Jaguar Animal Health -169.04% N/A -115.55%

Which has stronger earnings & valuation, CERO or PPBT?

Purple Biotech is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CERo Therapeutics N/A N/A -$8.30M -$71.01 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is CERO or PPBT more profitable?

CERo Therapeutics' return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Purple Biotech N/A -123.63% -98.72%

Do analysts recommend CERO or ITRM?

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 294,017.65%. Given CERo Therapeutics' higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is CERO or ITRM more profitable?

Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Iterum Therapeutics N/A N/A -65.54%

Do analysts recommend ABP or CERO?

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 294,017.65%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Abpro. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation and earnings, ABP or CERO?

Abpro is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A CERo Therapeutics N/A N/A -$8.30M -$71.01 N/A

Is ABP or CERO more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% CERo Therapeutics N/A N/A -209.40%

Do analysts recommend ELAB or CERO?

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 294,017.65%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is ELAB or CERO more profitable?

CERo Therapeutics' return on equity of 0.00% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics (CERO) Competitors

$0.01 0.00 (-12.07%)

As of 07/6/2026 03:55 PM Eastern

Compare

CERO vs. JAGX, PPBT, ITRM, ABP, and ELAB

Should you buy CERo Therapeutics stock or one of its competitors? MarketBeat compares CERo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CERo Therapeutics include Jaguar Animal Health (JAGX), Purple Biotech (PPBT), Iterum Therapeutics (ITRM), Abpro (ABP), and PMGC (ELAB). These companies are all part of the "pharmaceutical products" industry.

How does CERo Therapeutics compare to Jaguar Animal Health?

CERo Therapeutics (NASDAQ:CERO) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

CERo Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 294,017.65%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CERo Therapeutics is more favorable than Jaguar Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CERo Therapeutics has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -169.04%.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Jaguar Animal Health	-169.04%	N/A	-115.55%

CERo Therapeutics has higher earnings, but lower revenue than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Jaguar Animal Health	$11.51M	0.15	-$53.43M	-$591.92	N/A

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Jaguar Animal Health'saverage media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Jaguar Animal Health	Neutral

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 2.0% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CERo Therapeutics beats Jaguar Animal Health on 8 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to Purple Biotech?

CERo Therapeutics (NASDAQ:CERO) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

CERo Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Purple Biotech	Neutral

CERo Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 294,017.65%. Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,634.10%. Given CERo Therapeutics' higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CERo Therapeutics' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Purple Biotech	N/A	-123.63%	-98.72%

Purple Biotech is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Summary

Purple Biotech beats CERo Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to Iterum Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

CERo Therapeutics has higher earnings, but lower revenue than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

CERo Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market.

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 294,017.65%. Given CERo Therapeutics' higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Iterum Therapeutics	N/A	N/A	-65.54%

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Iterum Therapeutics	Neutral

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Iterum Therapeutics beats CERo Therapeutics on 5 of the 9 factors compared between the two stocks.

How does CERo Therapeutics compare to Abpro?

Abpro (NASDAQ:ABP) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
CERo Therapeutics	N/A	N/A	-209.40%

In the previous week, Abpro's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
CERo Therapeutics	Neutral

23.3% of Abpro shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abpro is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 294,017.65%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

CERo Therapeutics beats Abpro on 5 of the 8 factors compared between the two stocks.

How does CERo Therapeutics compare to PMGC?

PMGC (NASDAQ:ELAB) and CERo Therapeutics (NASDAQ:CERO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 294,017.65%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

PMGC has higher revenue and earnings than CERo Therapeutics. PMGC is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$590K	2.63	-$7.75M	-$168.62	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

22.2% of PMGC shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 0.0% of PMGC shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CERo Therapeutics' return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
CERo Therapeutics	N/A	N/A	-209.40%

PMGC has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the broader market.

In the previous week, PMGC had 4 more articles in the media than CERo Therapeutics. MarketBeat recorded 4 mentions for PMGC and 0 mentions for CERo Therapeutics. PMGC's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
PMGC	Neutral
CERo Therapeutics	Neutral

Summary

CERo Therapeutics beats PMGC on 7 of the 11 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERO vs. The Competition

Export

Metric	CERo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$460K	$3.10B	$6.92B	$12.59B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	0.00	20.05	27.35	24.81
Price / Sales	N/A	383.84	507.73	89.92
Price / Cash	N/A	57.18	29.65	49.23
Price / Book	0.00	4.36	11.06	6.50
Net Income	-$8.30M	$64.65M	$3.57B	$336.03M
7 Day Performance	N/A	1.26%	2.56%	2.68%
1 Month Performance	N/A	7.16%	7.39%	5.50%
1 Year Performance	N/A	29.42%	34.13%	25.01%

CERo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERO CERo Therapeutics	0.819 of 5 stars	$0.01 -12.1%	$30.00 +294,017.6%	-99.9%	$460K	N/A	N/A	8	Gap Up
JAGX Jaguar Animal Health	0.203 of 5 stars	$3.00 +1.4%	N/A	-96.9%	$1.79M	$11.51M	N/A	50
PPBT Purple Biotech	1.8527 of 5 stars	$1.68 -3.4%	$30.00 +1,685.7%	-93.1%	$1.62M	N/A	N/A	20
ITRM Iterum Therapeutics	0.036 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CERo Therapeutics (CERO) Competitors

CERO vs. JAGX, PPBT, ITRM, ABP, and ELAB

How does CERo Therapeutics compare to Jaguar Animal Health?

Summary

How does CERo Therapeutics compare to Purple Biotech?

Summary

How does CERo Therapeutics compare to Iterum Therapeutics?

Summary

How does CERo Therapeutics compare to Abpro?

Summary

How does CERo Therapeutics compare to PMGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CERo Therapeutics (CERO) Competitors

CERO vs. JAGX, PPBT, ITRM, ABP, and ELAB

How does CERo Therapeutics compare to Jaguar Animal Health?

Which has more risk and volatility, CERO or JAGX?

Do analysts rate CERO or JAGX?

Is CERO or JAGX more profitable?

Which has higher earnings & valuation, CERO or JAGX?

Does the media refer more to CERO or JAGX?

Do insiders & institutionals believe in CERO or JAGX?

Summary

How does CERo Therapeutics compare to Purple Biotech?

Which has more risk & volatility, CERO or PPBT?

Does the media prefer CERO or PPBT?

Do analysts rate CERO or PPBT?

Do insiders and institutionals have more ownership in CERO or PPBT?

Is CERO or PPBT more profitable?

Which has stronger earnings & valuation, CERO or PPBT?

Summary

How does CERo Therapeutics compare to Iterum Therapeutics?

Which has better valuation & earnings, CERO or ITRM?

Which has more volatility & risk, CERO or ITRM?

Do analysts recommend CERO or ITRM?

Is CERO or ITRM more profitable?

Does the media prefer CERO or ITRM?

Do institutionals & insiders have more ownership in CERO or ITRM?

Summary

How does CERo Therapeutics compare to Abpro?

Is ABP or CERO more profitable?

Does the media refer more to ABP or CERO?

Do institutionals and insiders hold more shares of ABP or CERO?

Which has stronger valuation and earnings, ABP or CERO?

Do analysts recommend ABP or CERO?

Summary

How does CERo Therapeutics compare to PMGC?

Do analysts recommend ELAB or CERO?

Which has higher valuation and earnings, ELAB or CERO?

Do institutionals & insiders have more ownership in ELAB or CERO?

Is ELAB or CERO more profitable?

Which has more volatility & risk, ELAB or CERO?

Does the media refer more to ELAB or CERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools